Want to cut your energy bills? Here’s how five experts are doing it 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
SEATTLE, Feb. 22, 2017 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston.
Brad Gray, president and chief executive officer, is scheduled to present on Tuesday, March 7, 2017 at 8:40 am ET. Interested parties can access the live webcast with accompanying slides from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit www.nanostring.com.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications [email protected] Phone: 206-602-1768
